Booster shot of COVID-19 vaccine developed by Pfizer/BioNTech can restore “full protection” from the virus, a study claimed.
Booster shot of the anti-COVID-19 vaccine developed by Pfizer/BioNTech has 95.6 percent efficacy, trial data published by the vaccine makers claimed.
The fast-spreading delta variant was the predominate strain during the trial.
The clinical phase three trial with “10,000 participants 16 years of age and older” showed “a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain”, the companies said in a statement.
“We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,” Pfizer Chief Executive Officer Albert Bourla said.
Several countries have already approved Covid-19 booster shots to increase immunity in people who have already been vaccinated, but whose protection may have dipped after several months, per some studies.